1[3]Lone J,Stanley BP,Patrick MJ,et al.Novel vinyl N-(2-benzoyl)-L-tyrosine derivatives and their use as antidiabeticsetc[P].WO:03/011834 A1,2003-02-13.
2[4]Lu XP,Li ZB,Li BY,et al.Substituted arylalcanoic acid derivatives as pan PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity[P].USP:US60/429221,2002-12-26.
4[6]Henke BR,Blanchard SG,Brackeen MF,et al.N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists.1.Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents[J].J Med Chem,1998,41(25):5020-5036.
5[7]Koev D,Ionescu-Trgoviste C,Rosenthal A,et al.Balaglitazone,a new thiazolidinedione,improves glucose and lipid control in patients with type Ⅱ diabetes[J].Diabetes,2003,52( Suppl 1 ) :530.
6[8]Imoto H,Sugiyama Y,Kimura H,et al. Studies on non-thiazolidinedione antidiabetic agents.2.Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents[J].Chem Pharm Bull,2003,51 ( 2 ): 138.
8[10]Kersey K,Floren LC,Pendleton B,et al.T0903131 ,a selective modulator of PPAR-gamma activity,increases adiponectin levels in healthy subjects[A].In:64th Annu Meet Sci Sess Am Diabetes Assoc[C].2004: 656-P.
9[11]McIntyre JA,Castaner J,Bayes M,et al.Tesaglitazar treatment of type Ⅱ diabetes,treatment of metabolic syndrome,PPAR α /PPAR γ agonist[J].Drugs Fut, 2003,28 ( 10 ): 959.
10[12]Hegarty BD,Furler SM,Oakes N,et al. Peroxisome Proliferator-Activated Receptor(PPAR)activation induces tissue-specific effects on fatty acid uptake and metabolism in vitro-a study using the novel PPAR α/γagonist tesaglitazar[J].Endocrinology,2004,145:3158.
